GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cynosure Inc (NAS:CYNO) » Definitions » EV-to-EBITDA

Cynosure (Cynosure) EV-to-EBITDA : 33.13 (As of Apr. 26, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Cynosure EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cynosure's enterprise value is $1,590.5 Mil. Cynosure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2016 was $48.0 Mil. Therefore, Cynosure's EV-to-EBITDA for today is 33.13.

The historical rank and industry rank for Cynosure's EV-to-EBITDA or its related term are showing as below:

CYNO's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 15.18
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Cynosure's stock price is $66.00. Cynosure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 was $0.590. Therefore, Cynosure's PE Ratio for today is 111.86.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Cynosure EV-to-EBITDA Historical Data

The historical data trend for Cynosure's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynosure EV-to-EBITDA Chart

Cynosure Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 144.80 12.94 19.47 18.74

Cynosure Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.47 18.28 19.12 18.92 18.74

Competitive Comparison of Cynosure's EV-to-EBITDA

For the Medical Devices subindustry, Cynosure's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cynosure's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cynosure's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cynosure's EV-to-EBITDA falls into.



Cynosure EV-to-EBITDA Calculation

Cynosure's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1590.450/48.004
=33.13

Cynosure's current Enterprise Value is $1,590.5 Mil.
Cynosure's EBITDA for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cynosure  (NAS:CYNO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cynosure's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=66.00/0.590
=111.86

Cynosure's share price for today is $66.00.
Cynosure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.590.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Cynosure EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cynosure's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynosure (Cynosure) Business Description

Traded in Other Exchanges
N/A
Address
Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
Executives
Thomas H Robinson director C/O CYNOSURE, INC., 5 CARISLE ROAD, WESTFORD MA 01886
Marina Hatsopoulos director 39 MANNING ROAD, BILLERICA MA 01821
George J Vojta director 340 PONDFFIELD ROAD, BROXVILLE NY 10708

Cynosure (Cynosure) Headlines

From GuruFocus

Steven Cohen Invests in Cynosure

By David Goodloe David Goodloe 04-26-2016

Cynosure: A Value Play on Vanity

By guruek Mike Havrilla 01-19-2009

Small Caps: Assessing Management Guidance and Analysts' Estimates

By Robert Abbott Robert Abbott 11-05-2018